{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:17:56Z","timestamp":1789784276852,"version":"4.0.1"},"reference-count":90,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1517\/13543784.2013.774373","type":"journal-article","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T09:27:11Z","timestamp":1361611631000},"page":"687-699","source":"Crossref","is-referenced-by-count":44,"title":["Investigational Janus kinase inhibitors"],"prefix":"10.1517","volume":"22","author":[{"given":"Constantine S","family":"Tam","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Center, Department of Hematology","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Leukemia Department","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,2,23]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.11.4.2057-2065.1991"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5237.800"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00055-8"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2012.07.004"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.11.4968-4978.2004"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205156200"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4824"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002030"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000018"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2210"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107748"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335042"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1006966"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270108"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194548"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410306"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138230"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-013748"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062125"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_1_34_1","first-page":"176","article-title":"Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 109\/L): a comparison to patients with normal or high starting platelet counts","volume":"120","author":"Talpaz M","year":"2012","unstructured":"Talpaz M, Paquette R, Afrin L, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 109\/L): a comparison to patients with normal or high starting platelet counts. ASH Annl Meet Abstr 2012;120:176","journal-title":"ASH Annl Meet Abstr"},{"key":"e_1_3_1_35_1","first-page":"177","article-title":"Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 109\/L and 99 x 109\/L","volume":"120","author":"Harrison CN","year":"2012","unstructured":"Harrison CN, Gisslinger H, Miller CB, et al. Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 109\/L and 99 x 109\/L. ASH Annl Meet Abstr 2012;120:177","journal-title":"ASH Annl Meet Abstr"},{"key":"e_1_3_1_36_1","first-page":"313","article-title":"Durable responses with the JAK1\/JAK2 inhibitor, INCB018424, in patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) refractory or intolerant to Hydroxyurea (HU)","volume":"116","author":"Verstovsek S","year":"2010","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1\/JAK2 inhibitor, INCB018424, in patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) refractory or intolerant to Hydroxyurea (HU). ASH Annl Meet Abstr 2010;116:313","journal-title":"ASH Annl Meet Abstr"},{"key":"e_1_3_1_37_1","first-page":"804","article-title":"Long-term efficacy and safety results from a phase II study of ruxolitinib in patients with polycythemia vera","volume":"120","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al. Long-term efficacy and safety results from a phase II study of ruxolitinib in patients with polycythemia vera. ASH Annl MeetAbstr 2012;120:804","journal-title":"ASH Annl MeetAbstr"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222133"},{"key":"e_1_3_1_39_1","first-page":"798","article-title":"Improved efficacy upon combined JAK1\/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease","volume":"118","author":"Baffert F","year":"2011","unstructured":"Baffert F, Evrot E, Ebel N, et al. Improved efficacy upon combined JAK1\/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. Annl Meet Abstr 2011;118:798","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_3_1_42_1","first-page":"118","article-title":"Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy","author":"Verstovsek S","year":"2011","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z, et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. Annl Meet Abstr 2011;118-793","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109555"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518"},{"key":"e_1_3_1_45_1","first-page":"800","article-title":"Long-Term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I","volume":"120","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Long-Term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Annl Meet Abstr 2012;120:800","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_46_1","first-page":"801","article-title":"Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with Best Available Therapy (BAT) for the treatment of Myelofibrosis (MF)","volume":"120","author":"Cervantes F","year":"2012","unstructured":"Cervantes F, Kiladjian J-J, Niederwieser D, et al. Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with Best Available Therapy (BAT) for the treatment of Myelofibrosis (MF). Annl Meet Abstr 2012;120:801","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_47_1","first-page":"1727","article-title":"Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms","volume":"120","author":"Mesa RA","year":"2012","unstructured":"Mesa RA, Gotlib J, Kantarjian HM, et al. Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms. Annl Meet Abstr 2012;120:1727","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_48_1","first-page":"1733","article-title":"Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I","volume":"120","author":"Mesa RA","year":"2012","unstructured":"Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. Annl Meet Abstr 2012;120:1733","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_49_1","first-page":"802","article-title":"Reductions in JAK2 V617F allele burden with ruxolitinib treatment in Comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with Best Available Therapy (BAT)","volume":"120","author":"Vannucchi AM","year":"2012","unstructured":"Vannucchi AM, Passamonti F, Al-Ali HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in Comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with Best Available Therapy (BAT). Annl Meet Abstr 2012;120:802","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_3_1_51_1","first-page":"2838","article-title":"The use of Erythropoietic-Stimulating Agents (ESAs) with ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF)","volume":"120","author":"McMullin MF","year":"2012","unstructured":"McMullin MF, Harrison CN, Niederwieser D, et al. The use of Erythropoietic-Stimulating Agents (ESAs) with ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF). Annl Meet Abstr 2012;120:2838","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_52_1","first-page":"2847","article-title":"Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials","volume":"120","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Kiladjian J-J, Mesa RA, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials. Annl Meet Abstr 2012;120:2847","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_53_1","first-page":"2844","article-title":"An individual patient supply program for ruxolitinib for the treatment of patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)","volume":"120","author":"Barosi G","year":"2012","unstructured":"Barosi G, Agarwal M, Zweegman S, et al. An individual patient supply program for ruxolitinib for the treatment of patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF). Annl Meet Abstr 2012;120:2844","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_54_1","first-page":"2841","article-title":"Ruxolitinib therapy in myelofibrosis: analysis of 241 patients treated in compassionate use (French \"ATU\" program) by the French Intergroup of Myeloproliferative Neoplasms (FIM)","volume":"120","author":"Andreoli A","year":"2012","unstructured":"Andreoli A, Rey J, Dauriac C, et al. Ruxolitinib therapy in myelofibrosis: analysis of 241 patients treated in compassionate use (French \"ATU\" program) by the French Intergroup of Myeloproliferative Neoplasms (FIM). Annl Meet Abstr 2012;120:2841","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_3_1_58_1","first-page":"120","article-title":"Combination treatment with JAK2 and PI3K inhibitors in myeloproliferative neoplasms","author":"Choong ML","year":"2012","unstructured":"Choong ML, Pecquet C, Tai SJ, et al. Combination treatment with JAK2 and PI3K inhibitors in myeloproliferative neoplasms. Annl Meet Abstr 2012;120-80","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_59_1","first-page":"708","article-title":"Combined inhibition of JAK2 and mTOR signaling results in enhanced efficacy in in-vitro and preclinical mouse models of JAK2V617F-driven myeloproliferative disease","volume":"120","author":"Vannucchi AM","year":"2012","unstructured":"Vannucchi AM, Bartalucci N, Bogani C, et al. Combined inhibition of JAK2 and mTOR signaling results in enhanced efficacy in in-vitro and preclinical mouse models of JAK2V617F-driven myeloproliferative disease. Annl Meet Abstr 2012;120:708","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.56"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.02.009"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8021"},{"key":"e_1_3_1_63_1","first-page":"2837","article-title":"A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or High-risk primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF","volume":"120","author":"Talpaz M","year":"2012","unstructured":"Talpaz M, Jamieson C, Gabrail NY, et al. A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or High-risk primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF. Annl Meet Abstr 2012;120:2837","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3775"},{"key":"e_1_3_1_65_1","doi-asserted-by":"crossref","unstructured":"Hexner EO Serdikoff C Jan M et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008.111:5663-71","DOI":"10.1182\/blood-2007-04-083402"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246363"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.148"},{"key":"e_1_3_1_68_1","first-page":"3905","article-title":"Phase I Dose-Escalation trial of SB1518, a Novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"114","author":"Verstovsek S","year":"2009","unstructured":"< >Verstovsek S, Odenike O, Scott B, et al. Phase I Dose-Escalation trial of SB1518, a Novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia\/polycythemia vera myelofibrosis. Annl Meet Abstr 2009;114:3905","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_69_1","first-page":"472","article-title":"First report of the phase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis (abstract 1144)","volume":"95","author":"Seymour J","year":"2010","unstructured":"Seymour J, To B, Goh A, et al. First report of the phase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis (abstract 1144). Haematologica 2010;95:472","journal-title":"Haematologica"},{"key":"e_1_3_1_70_1","first-page":"378","article-title":"Long-term safety and efficacy analysis of the two phase 1 studies of SB1518, a novel oral JAK2 inhibitor, in patients with advanced myeloid malignancies (abstract 0907)","volume":"96","author":"Seymour J","year":"2011","unstructured":"Seymour J, Scott B, Robert A, et al. Long-term safety and efficacy analysis of the two phase 1 studies of SB1518, a novel oral JAK2 inhibitor, in patients with advanced myeloid malignancies (abstract 0907). Haematologica 2011;96:378","journal-title":"Haematologica"},{"key":"e_1_3_1_71_1","first-page":"282","article-title":"Results of a phase 2 study of pacritinib (sb1518), a novel oral jak2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis","volume":"118","author":"Komrokji RS","year":"2011","unstructured":"Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (sb1518), a novel oral jak2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Annl Meet Abstr 2011;118:282","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.50"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"e_1_3_1_74_1","first-page":"460","article-title":"A phase I\/II study of CYT387, an oral JAK-1\/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms","volume":"116","author":"Pardanani A","year":"2010","unstructured":"Pardanani A, George G, Lasho T, et al. A phase I\/II study of CYT387, an oral JAK-1\/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. ASH Annl Meet Abstr 2010;116:460","journal-title":"ASH Annl Meet Abstr"},{"key":"e_1_3_1_75_1","first-page":"3849","article-title":"An expanded multicenter phase I\/II study of CYT387, a JAK- 1\/2 inhibitor for the treatment of myelofibrosis","volume":"118","author":"Pardanani A","year":"2011","unstructured":"Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I\/II study of CYT387, a JAK- 1\/2 inhibitor for the treatment of myelofibrosis. ASH Annl MeetAbstr 2011;118:3849","journal-title":"ASH Annl MeetAbstr"},{"key":"e_1_3_1_76_1","first-page":"178","article-title":"Phase I\/II study of CYT387, a JAK1\/JAK2 inhibitor for the treatment of myelofibrosis","volume":"120","author":"Pardanani A","year":"2012","unstructured":"Pardanani A, Gotlib J, Gupta V, et al. Phase I\/II study of CYT387, a JAK1\/JAK2 inhibitor for the treatment of myelofibrosis. ASH Annl Meet Abstr 2012;120:178","journal-title":"ASH Annl Meet Abstr"},{"key":"e_1_3_1_77_1","first-page":"553","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"110","author":"Verstovsek S","year":"2007","unstructured":"Verstovsek S, Pardanani A, Shah N, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis. Annl Meet Abstr 2007;110:553","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_78_1","first-page":"98","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis","volume":"112","author":"Shah NP","year":"2008","unstructured":"Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Annl Meet Abstr 2008;112:98","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_79_1","first-page":"2810","article-title":"A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera","volume":"112","author":"Paquette R","year":"2008","unstructured":"Paquette R, Sokol L, Shah NP, et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Annl Meet Abstr 2008;112:2810","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_80_1","first-page":"4087","article-title":"Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models","volume":"116","author":"Ma L","year":"2010","unstructured":"Ma L, Zhao B, Walgren R, et al. Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models. Annl Meet Abstr 2010;116:4087","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_81_1","first-page":"2814","article-title":"Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)","volume":"118","author":"Verstovsek S","year":"2011","unstructured":"Verstovsek S, Mesa RA, Rhoades SK, et al. Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). Annl Meet Abstr 2011;118:2814","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.292"},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.29"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.10.015"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-446849"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64397"},{"key":"e_1_3_1_87_1","first-page":"1752","article-title":"JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis","volume":"120","author":"Wang X","year":"2012","unstructured":"Wang X, Tripodi J, Novak J, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Annl Meet Abstr 2012;120:1752","journal-title":"Annl Meet Abstr"},{"key":"e_1_3_1_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.255"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_3_1_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11303"},{"key":"e_1_3_1_91_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111694"},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2011.08.002"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2013.774373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:07:26Z","timestamp":1770898046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2013.774373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,23]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1517\/13543784.2013.774373"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2013.774373","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,23]]}}}